Inhibikase Therapeutics Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 17 | Q4 17 | Q1 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | 100.0% | – | – | – | – | – | – | – | |
| 103.8% | 100.0% | 84.7% | 100.0% | 263.2% | 284.0% | 204.9% | 111.5% | 104.6% | 119.9% | 320.0% | 133.2% | 172.8% | 174.8% | 960.4% | 174,396.0% | 6,554.3% | 45,515.6% | 23.1% | 4.1% | 7.8% | 136.8% | 8.3% | 656,800.0% | – | – | – | 25.0% | – | – | – | – | – | – | – | |
| -3.8% | – | 15.3% | – | -163.2% | -184.0% | -104.9% | -11.5% | -4.6% | -19.9% | -220.0% | -33.2% | -72.8% | -74.8% | -860.4% | -174,296.0% | -6,454.3% | -45,415.6% | 76.9% | 95.9% | 92.2% | -36.8% | 91.7% | -656,700.0% | – | – | – | -25.0% | – | – | – | – | – | – | – | |
| 103.8% | 75.3% | 84.7% | 108.6% | 263.2% | 284.0% | 204.9% | 111.5% | 104.6% | 119.9% | 320.0% | 133.2% | 172.8% | 174.8% | 960.4% | 174,396.0% | 6,554.3% | 45,515.6% | 40,895.0% | 2,474.2% | 4,423.6% | 3,896.3% | 4,053.8% | 300,298,000.0% | – | – | – | 27,354.0% | – | – | – | – | – | – | – | |
| – | – | – | – | 129.9% | 1,217.0% | – | 164.2% | 194.9% | 168.7% | 1,541.5% | 1,539.3% | 186.4% | 118.0% | 500.8% | 85,038.4% | 3,627.2% | 25,401.5% | 21,104.6% | 1,089.1% | 2,984.1% | 1,531.8% | 2,039.6% | 140,058,700.0% | – | – | – | 21,828.2% | – | – | – | – | – | – | – | |
| 68.6% | 93.2% | 31.7% | 193.6% | 293.1% | 1,400.9% | 968.1% | 164.2% | 194.9% | 168.7% | 1,541.5% | 671.5% | 113.7% | 118.0% | 500.8% | 85,038.4% | 3,627.2% | 25,401.5% | 61,976.5% | 3,511.8% | 7,399.9% | 5,291.3% | 6,085.1% | 439,699,900.0% | – | – | – | 49,182.2% | – | – | – | – | – | – | – | |
| -72.5% | 6.8% | -16.4% | -93.6% | -293.1% | -1,400.9% | -968.1% | -175.7% | -199.4% | -188.5% | -1,761.4% | -704.7% | -186.6% | -192.8% | -1,361.2% | -259,334.4% | -10,081.5% | -70,817.1% | -61,899.6% | -3,511.8% | -7,307.7% | -5,328.1% | -5,993.4% | -440,356,600.0% | – | – | – | -49,207.2% | – | – | – | – | – | – | – | |
| – | 1.2% | – | 0.4% | 0.6% | 3.4% | 6.3% | 3.2% | 2.7% | 3.6% | 18.3% | 4.2% | 0.8% | 0.6% | 0.0% | 8.1% | 0.0% | 0.0% | 254.2% | 45.3% | 367.6% | 364.6% | 70.3% | 66,160,600.0% | – | – | – | – | – | – | – | – | – | – | – | |
| -75.0% | 5.6% | -18.1% | -94.0% | -293.7% | -1,404.3% | -974.4% | -179.0% | -202.2% | -192.1% | -1,779.7% | -708.8% | -187.4% | -193.4% | -1,361.3% | -259,342.5% | -10,081.5% | -70,817.1% | -61,645.4% | -3,466.5% | -6,940.1% | -4,963.5% | -5,775.1% | -417,794,000.0% | – | – | – | -46,177.1% | – | – | – | – | – | – | – | |
| -2.6% | – | -1.7% | – | -293.1% | -1,400.9% | -968.1% | -175.7% | -199.4% | -188.5% | -1,761.4% | -1,667.0% | -186.6% | -192.8% | -1,361.2% | -16.2% | -10,081.5% | -70,817.1% | -508.5% | -90.6% | -735.2% | 31.9% | 58.0% | 100.0% | – | – | – | – | – | – | – | – | – | – | – | |
| -75.0% | 5.6% | -18.1% | -94.0% | -293.7% | -1,404.3% | -974.4% | -179.0% | -202.2% | -192.1% | -1,779.7% | -708.8% | -187.4% | -193.4% | -1,361.3% | -259,342.5% | -10,081.5% | -70,817.1% | -61,645.4% | -3,375.9% | -6,940.1% | -4,963.5% | -5,775.1% | -417,794,000.0% | – | – | – | -46,177.1% | – | – | – | – | – | – | – | |
| – | 6.8% | – | -93.6% | -293.1% | -1,400.9% | -968.1% | -175.7% | -199.4% | -188.5% | -1,761.4% | -704.7% | -186.6% | -192.8% | -1,361.2% | -259,334.4% | -10,081.5% | -70,817.1% | -61,622.3% | -3,522.7% | -6,932.3% | -4,826.7% | -5,766.9% | -417,137,200.0% | – | – | – | -46,152.1% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.